Details of the Drug Reposition

General Information of This Drug (ID: DMRJ3ND)

Drug Name
CD19 and CD20 CAR-T Cells   DMRJ3ND
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Phase 1/2 [1]
B-cell lymphoma DISIH1YQ 2A86 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma